Spark Therapeutics (ONCE) Stock Rating Reaffirmed by William Blair

Share on StockTwits

William Blair restated their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note published on Tuesday. William Blair also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($0.69) EPS, Q1 2019 earnings at ($1.00) EPS, Q2 2019 earnings at ($1.04) EPS, Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.73) EPS, FY2019 earnings at ($3.17) EPS, FY2020 earnings at ($3.83) EPS, FY2021 earnings at ($4.85) EPS and FY2022 earnings at ($4.46) EPS.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus decreased their target price on shares of Spark Therapeutics from $76.00 to $68.00 and set a buy rating for the company in a report on Wednesday, August 8th. UBS Group decreased their target price on shares of Spark Therapeutics from $80.00 to $53.00 and set a neutral rating for the company in a report on Wednesday, August 8th. Royal Bank of Canada decreased their target price on shares of Spark Therapeutics to $64.00 and set a sector perform rating for the company in a report on Wednesday, August 8th. BMO Capital Markets cut shares of Spark Therapeutics from an outperform rating to a market perform rating and set a $60.00 target price for the company. in a report on Tuesday, August 7th. Finally, Leerink Swann reaffirmed a market perform rating and issued a $55.00 target price (down from $74.00) on shares of Spark Therapeutics in a report on Tuesday, August 7th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $68.52.

NASDAQ:ONCE traded down $3.24 during mid-day trading on Tuesday, hitting $42.76. 666,734 shares of the company’s stock were exchanged, compared to its average volume of 567,755. Spark Therapeutics has a one year low of $39.01 and a one year high of $96.59. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 18.14. The firm has a market capitalization of $1.71 billion, a P/E ratio of -5.60 and a beta of 2.27.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.22). The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The firm’s quarterly revenue was up 463.2% on a year-over-year basis. During the same period last year, the firm posted ($1.90) earnings per share. On average, equities research analysts expect that Spark Therapeutics will post -1.44 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC increased its holdings in Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after buying an additional 1,056 shares during the last quarter. Tocqueville Asset Management L.P. increased its holdings in Spark Therapeutics by 2.7% during the second quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock valued at $3,412,000 after buying an additional 1,075 shares during the last quarter. Amalgamated Bank increased its holdings in Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 1,100 shares during the last quarter. Smith Asset Management Group LP increased its holdings in Spark Therapeutics by 39.6% during the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 1,120 shares during the last quarter. Finally, Capital Fund Management S.A. increased its holdings in Spark Therapeutics by 8.1% during the second quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock valued at $1,273,000 after buying an additional 1,152 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: What is an Initial Public Offering (IPO)?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rayonier Inc.  Holdings Reduced by Forsta AP Fonden
Rayonier Inc. Holdings Reduced by Forsta AP Fonden
Zacks: Brokerages Expect DiamondRock Hospitality  to Announce $0.26 Earnings Per Share
Zacks: Brokerages Expect DiamondRock Hospitality to Announce $0.26 Earnings Per Share
Granite Investment Advisors LLC Cuts Stake in Honeywell International Inc.
Granite Investment Advisors LLC Cuts Stake in Honeywell International Inc.
Forsta AP Fonden Reduces Position in Waste Connections Inc
Forsta AP Fonden Reduces Position in Waste Connections Inc
Edgestream Partners L.P. Acquires 11,229 Shares of Tapestry Inc
Edgestream Partners L.P. Acquires 11,229 Shares of Tapestry Inc
Edgestream Partners L.P. Takes $719,000 Position in SunTrust Banks, Inc.
Edgestream Partners L.P. Takes $719,000 Position in SunTrust Banks, Inc.


Leave a Reply

© 2006-2018 Ticker Report